NCT06283550

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Innovaderm Research Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Detailed description

This randomized, double-blind, placebo-controlled, multicenter, phase 2 study aims to evaluate the efficacy of abrocitinib in 84 adult subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Conditions

• Chronic Hand Eczema

Interventions

Type	Name	Description
DRUG	Abrocitinib 200 mg	Abrocitinib will be available in 100 mg strength tablet
DRUG	Abrocitinib 100 mg	Abrocitinib will be available in 100 mg strength tablet
DRUG	Placebo	Placebo tablet

Timeline

• Start date: 2024-05-31
• Primary completion: 2025-06-18
• Completion: 2025-11-03
• First posted: 2024-02-28
• Last updated: 2026-02-03

Locations

12 sites across 2 countries: Canada, Poland

Regulatory

• FDA-regulated drug study